Harvia’s Half-year financial review 1 January – 30 June 2026

Harvia reported Q2 2026 revenue of EUR 52.8m, up 11.7% YoY (12.9% at comparable FX), with North America driving growth (+38.6% revenue) and operating profit rising to EUR 8.4m. Profitability was temporarily pressured by an IT/process upgrade at the Muurame site, postponing ~EUR 4m of deliveries and related gross margin into Q3, while adjusted operating profit was EUR 8.6m (16.2% margin). For 1H 2026, revenue grew 12.2% to EUR 111.4m and operating free cash flow improved to EUR 15.1m, though cash conversion eased vs prior year and net debt remained roughly flat at EUR 57.2m.

Analysis

The key market mechanism is not demand weakness but timing distortion: the quarter created a visible near-term earnings dip while effectively pushing a meaningful amount of revenue/gross profit into the next print. That sets up a cleaner 3Q comp than the headline numbers imply, especially if management can show the factory/process reset is fully normalized and North America remains the incremental growth engine. In other words, this is more likely a sequencing event than a fundamental slowdown, which usually supports an after-the-dip re-rating in small-cap industrial consumer names.

The second-order issue is mix. North America appears to be becoming the margin pool, while steam products and parts of Europe are acting as drag, so the long-term question is whether higher-growth U.S. distribution can offset structurally softer channels elsewhere. If U.S. growth is being amplified by broader wellness adoption and expanded distribution rather than one-off project deliveries, the upside is that Harvia can compound above its target without needing M&A; the downside is concentration risk if U.S. sell-through normalizes faster than expected.

The contrarian takeaway is that the market may be over-penalizing a delivery postponement that should partially reverse next quarter. What would falsify the bullish read is not one weak quarter, but a 2H sequential slowdown in North America, continued steam deterioration, or evidence that the IT project damaged customer relationships rather than merely lead times. Geopolitical softness in the Middle East is the cleaner structural headwind and likely stays a 6-12 month drag, but it is not enough on its own to break the investment case if the U.S. remains intact.

Key Decisions for Investors

• Lean long HRVFF on weakness over the next 1-3 weeks, but size modestly given OTC liquidity; the setup is a 1-quarter timing shift rather than a thesis reset, with upside into the next report if the deferred deliveries flow through as expected.
• Use a staged buy/watch level rather than chasing the print: add only if management commentary confirms 3Q normalization and North America orders remain strong; if 3Q revenue fails to show a visible catch-up, the thesis is weakened.
• For more aggressive exposure, consider a call spread in HRVFF covering the next earnings cycle to express the timing rebound while capping liquidity/volatility risk; this is best if implied vol remains muted after the release.
• Watch for a relative-value long HRVFF vs. short a broader European discretionary/home-goods proxy if the market keeps pricing this as demand deterioration; the edge is in deferred revenue conversion, not macro beta.
• Falsify/exit if North America growth decelerates sharply or if gross margin stays below prior-run rates after the Muurame normalization, which would indicate the quarter was not just a one-off operational lag.